Podcasts about Genomics

Sophie Sargent walked into the studio already owning the mic. A pandemic-era media rebel raised in New Hampshire, trained in Homeland Security (yep), and shaped by rejection, she's built a career out of DM'ing her way into rooms and then owning them. At 25, she's juggling chronic illness, chronic overachievement, and a generation that gets dismissed before it even speaks.We talk Lyme disease, Lyme denial, and the healthcare gaslighting that comes when you “look fine” but your body says otherwise. We dive into rejection as a career accelerant, mental health as content porn, and what it means to chase purpose without sacrificing identity. Sophie's a former morning radio host, country music interviewer, and Boston-based creator with a real voice—and she uses it.No fake podcast voice. No daddy-daughter moment. Just two loudmouths from different planets figuring out what it means to be seen, believed, and taken seriously in a system designed to do the opposite.Spoiler: She's smarter than I was at 25. And she'll probably be your boss someday.RELATED LINKSSophie on InstagramSophie on YouTubeSophie on LinkedInMedium article: “Redefining Rejection”See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

What happens when you hand a mic to the most extroverted, uncensored Gen Z career coach in New York? You get Olivia Battinelli—adjunct professor, student advisor, mentor, speaker, and unfiltered truth-teller on everything from invisible illness to resume crimes.We talked about growing up Jewish-Italian in Westchester, surviving the Big Four's corporate Kool-Aid, and quitting a job after 7 months because the shower goals weren't working out. She runs NYU Steinhardt's internship program by day, roasts Takis and “rate my professor” trolls by night, and somehow makes room for maple syrup takes, career coaching, and a boyfriend named Dom who sounds like a supporting character from The Sopranos.She teaches kids how to talk to humans. She's allergic to BS. And she might be the most Alexis Rose-meets-Maeve Wiley-mashup ever dropped into your feed. Welcome to her first podcast interview. It's pure gold.RELATED LINKS:Olivia Battinelli on LinkedInOlivia's Liv It Up Coaching WebsiteOlivia on InstagramNYU Steinhardt Faculty PageFEEDBACK:Like this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

On today's Unemployable, we tackle the hard stuff: why cancer remains our biggest health challenge, why water quality may define the next global conflict, how outbreaks re-enter the U.S. (measles, dengue, bioterror), what COVID actually taught us, and where AI and genomics help—or create new risks. Along the way we talk access to care, compounding vs. brand-name drugs, GLP-1s (Ozempic/Wegovy), and the habits that really move the needle: sleep, strength, hydration, and walking with purpose. My guest is a former U.S. Assistant Secretary for Health and four-star admiral in the U.S. Public Health Service with leadership roles spanning MD Anderson's Moon Shots, WHO, and federal response teams for anthrax and Ebola. It's a masterclass in population health, plain talk, and what leaders should actually do next. Timestamps below. If this helps you think clearer and lead better, hit subscribe and share it with one person who needs it today. Disclaimers: This show is educational only. Nothing here is medical advice. Talk to your doctor before making decisions about screening, vaccines, medications, or treatment. Resources mentioned: • Joxel Garcia's books on Amazon • St. Jude Children's Research Hospital • MD Anderson Moon Shots • CDC/WHO resources on vaccines & outbreaks 

On today's Unemployable, we tackle the hard stuff: why cancer remains our biggest health challenge, why water quality may define the next global conflict, how outbreaks re-enter the U.S. (measles, dengue, bioterror), what COVID actually taught us, and where AI and genomics help—or create new risks. Along the way we talk access to care, compounding vs. brand-name drugs, GLP-1s (Ozempic/Wegovy), and the habits that really move the needle: sleep, strength, hydration, and walking with purpose. My guest is a former U.S. Assistant Secretary for Health and four-star admiral in the U.S. Public Health Service with leadership roles spanning MD Anderson's Moon Shots, WHO, and federal response teams for anthrax and Ebola. It's a masterclass in population health, plain talk, and what leaders should actually do next. Timestamps below. If this helps you think clearer and lead better, hit subscribe and share it with one person who needs it today. Disclaimers: This show is educational only. Nothing here is medical advice. Talk to your doctor before making decisions about screening, vaccines, medications, or treatment. Resources mentioned: • Joxel Garcia's books on Amazon • St. Jude Children's Research Hospital • MD Anderson Moon Shots • CDC/WHO resources on vaccines & outbreaks 

On this episode of The Digital Patient, Dr. Joshua Liu, Co-founder & CEO of SeamlessMD, and colleague, Alan Sardana, chat with Dr. Albert Bonnema, CMIO at Kettering Health, about "Combining EHR, genomics, and AI for breakthroughs in precision medicine, Risks of AI use in medical education, Barriers to making personalized medicine standard, and more..."

In this explainer episode, we've asked Dr Nour Elkhateeb, clinical fellow at Genomics England and clinical geneticist for the NHS, to explain the role of a clinical geneticist. The previous episode mentioned in the conversation is linked below. What is the diagnostic odyssey? You can also find a series of short videos explaining some of the common terms you might encounter about genomics on our YouTube channel. If you've got any questions, or have any other topics you'd like us to explain, let us know on podcast@genomicsengland.co.uk. You can download the transcript or read it below. Florence: What is a clinical geneticist? My name is Florence Cornish and I'm here with Nour Elkhateeb, clinical geneticist for the NHS and fellow at Genomics England, to find out more. So, Nour, before we dive into talking about clinical geneticists, could you explain what we mean by the term genetics? Nour: Hi Florence, so at its heart, genetics is the study of our genes and how they are passed down through families. Think of your genome as a huge, incredibly detailed instruction manual for building and running your body. This manual is written in a specific language, DNA, which is made up of millions of letters arranged in a specific order.  And here is the interesting part, we all have tiny differences in our genetic spelling, which is what makes each of us unique.  But sometimes a change in the instructions, a spelling mistake in a critical place, can affect health. Genetics is all about learning to read that manual, understand how changes in it can cause disease, how it's passed down through families and finding ways to help.   Florence: And so, what kind of thing does a geneticist actually do? Nour: Well, the term geneticist can cover a few different roles, which often work together. Crudely speaking, you can think of two main types, laboratory geneticists and clinical geneticists.   Laboratory geneticists are the incredible scientists who work behind the scenes. When we send a blood sample for genomic sequencing, they are the ones who use amazing technology to read the billions of letters in that person's instruction manual. The job is to find the one tiny spelling mistake among those billions of letters that might be causing a health problem.  Clinical geneticists like me are medical doctors specialised in the field of genetics, and we work face-to-face with patients and families in a hospital or a clinic setting. You can think of us as the bridge between the incredibly complex science of the genomics lab and the real-life health journey of the person in front of them. We diagnose, manage and provide support for individuals and families who are affected by or at risk of genetic conditions. And we translate that complex genetic information into meaningful information for the patient, the family and the other doctors as well.  Florence: So, let's talk a little bit more about clinical geneticists. What stage of someone's genomics journey are they likely to see you? What are some typical reasons they might get referred, for example?  Nour: That's a really good question. So, people actually can be seen by clinical geneticists at almost any stage of life, and for many different reasons. Let me give you some examples.  We see a lot of babies and children. A family may be referred to us if their baby is born with health problems that do not have a clear cause, or if a child is not developing as expected. And sometimes families may have been searching for answers for years, or what we call a diagnostic odyssey, but no one has been able to find a single unifying diagnosis to explain their challenges. And our job is to see if there is a genetic explanation that can connect all the dots.  Florence: You touched there on the diagnostic odyssey, and I know we don't have time to dive into that right now, but if listeners want to learn more about this, then they can check out our previous Genomics 101 podcast: What is the Diagnostic Odyssey? So, Nour, we know that you see children and families in their genomics journeys. Do you see adults as well?  Nour: Yes, indeed. We also see many adults who develop certain health conditions, such as cancer or certain types of heart disease, and their clinicians suspect they might be having an underlying inherited genetic cause, or it could be actually someone who is healthy themselves, but have a family history of a particular condition, and want to understand their own risk or the risk for their children and other family members. A classic example is in cancer genetics. A woman with breast cancer at a young age, or who has several family members who have also had it, she would be investigated to see if she carries a gene change that increases the risk of breast cancer and other cancers, and finding that actually would be critical for the treatment choices, and it has huge implications for her relatives.  Also, a major part of our work is in the prenatal setting, so we might see a couple during a pregnancy if the antenatal ultrasound scan, for example, shows that the baby has abnormalities. And the obstetrician might refer them to us to investigate if they have an underlying genetic reason for that. And this can help the couple and the medical team prepare for any challenges after birth and also make informed decisions about the pregnancy.   And clinical genetics is unique in that we don't see just individual patients, we often work with entire families, and if there is an inherited condition in the family, it's not unusual for several relatives across different generations to be seen by our team.  This family-wide approach helps us piece together the inheritance pattern and offer the right tests to the right people, and also ensure that everyone who might benefit from information or screening has the opportunity to access that.  Florence: So if someone has a suspected genetic condition, will they always come to you first?  Nour: Actually no, the way people come to us is changing. It used to be that you would always see clinical geneticists first, but now with genetic testing becoming more common, other clinicians like a cardiologist, a neurologist, or a paediatrician, might order a genetic test themselves.   But these tests can produce a huge amount of data, and the results are not always a simple yes or no. Sometimes the lab finds something called a variant of uncertain significance, which means a gene change that we are not certain whether it is the cause of health problems or not. And in these cases, a specialist will refer the patient to us to help put the uncertain result into the context of the patient's specific health problems, and family history, and to help also work out what it really means for them and their family.  Florence: So, you mentioned a couple of other healthcare professionals there, paediatricians and neurologists for example. Are there any other roles that you work closely with as a clinical geneticist?  Nour: Well, genetics is never a one-person job, and it's rather like a team sport, so we never work in isolation. We work in what we call a multidisciplinary team,  where clinical geneticists, genetic counsellors, genomic practitioners, scientists and other specialists, all bring our knowledge and expertise together. We also work directly with other specialists across the hospital and the NHS. Let's say if it's a genetic heart condition, a cardiologist would be a key part of this multidisciplinary team for the patient. And this 360-degree view ensures that we are giving the best possible holistic care.   Florence: And finally, before we wrap up, I'm sure lots of our listeners may have heard or even come across genetic counsellors. Could you explain how this role is different from a clinical geneticist?  Nour: So, our role as a clinical geneticist is distinct from that of a genetic counsellor, but we work side by side. Clinical geneticists, as the medical doctors on the team, we're often focused on the diagnosis, and we will perform a physical examination of the patient, looking for subtle clues. We will review their medical history, and piece together the whole medical puzzle. And based on that, we decide which genetic test is the most appropriate, and we'll have the best chance of finding an answer. A genetic counsellor is a healthcare professional with highly specialised training in both genetics and counselling. They are communication experts, they spend time helping families understand results, process the information, and think through what it means for them and their relatives. They are incredibly skilled at explaining complex genetic concepts in a way that is easy to understand, and also at providing support. They help families navigate the emotional impact of what can be life-changing news, and also discuss the implications for the wider family. And genetic counsellors are not only there after the diagnosis is made, they can also play an active role in the diagnostic process.  So in many situations, they are the ones taking the detailed family history, recognising patterns that suggest a genetic condition, and arrange the most appropriate genetic tests. They work closely with laboratory scientists and clinical geneticists to interpret the results and guide the next steps for the patient.  And a family will often see both of us as our roles complement each other.  Florence: So, we'll finish there. Thank you so much, Nour, for sharing what you do as a clinical geneticist.   If you'd like to hear more explainer episodes like this, you can find them on our website at www.genomicsengland.co.uk, or wherever you get your podcasts. Thank you for listening. 

This episode is sponsored by Invivyd, Inc.Marc Elia is a biotech investor, the Chairman of the Board at Invivyd, and a Long COVID patient who decided to challenge the system while still stuck inside it. He's not here for corporate platitudes, regulatory shoulder shrugs, or vaccine-era gaslighting. This is not a conversation about politics, but it's about power and choice and the right to receive care and treatment no matter your condition.In this episode, we cover everything from broken clinical pathways to meme coins and the eternal shame of being old enough to remember Eastern Airlines. Marc talks about what it means to build tools instead of just complaining, what Long COVID has done to his body and his patience, and why the illusion of “choice” in healthcare is a luxury most patients don't have.This conversation doesn't ask for empathy. It demands it.RELATED LINKSMarc Elia on LinkedInInvivyd Company SiteMarc's Bio at InvivydFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

After years of carrying the weight of lead, Shannon and Cooper find a path out from under the darkness and into the sunlight.LEAD: how this story ends is up to us is an audio docudrama series that tells the true story of one child, his mysterious lead poisoning, and his mother's unwavering fight to keep him safe. A true story written by Shannon Burkett. Directed by Alan Taylor. Starring Merritt Wever, Alessandro Nivola, Cynthia Nixon, and Cooper Burkett.Lead was produced by Shannon Burkett. Co-produced by Jenny Maguire. Featuring Amy Acker, Tom Butler, Dennis T. Carnegie, James Carpinello, Geneva Carr, Dann Fink, Alice Kris, Adriane Lenox, Katie O'Sullivan, Greg Pirenti, Armando Riesco, Shirley Rumierk, Thom Sesma, and Lana Young. Music by Peter Salett. “Joy In Resistance” written by Abena Koomson-Davis and performed by Resistance Revival Chorus. Casting by Alaine Alldaffer and Lisa Donadio. Sound Design by Andy Kris. Recording Engineer Krissopher Chevannes.For corresponding visuals and more information on how to protect children from lead exposure please go to https://endleadpoisoning.org.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Urologic oncologist Dr. Peter Carroll presents the latest research on active surveillance as a preferred approach for managing low-risk prostate cancer and selected cases of intermediate-risk disease. Drawing from two decades of UCSF data, he explains how long-term outcomes support the safety and effectiveness of delaying treatment for carefully monitored patients. Carroll emphasizes that surveillance decisions should be guided by MRI imaging, PSA density, cancer volume, histologic subtype, and genomic testing. He notes that while many men experience gradual changes over time, only a small percentage require immediate treatment. Carroll also discusses innovations such as AI-assisted pathology and risk profiling to reduce unnecessary procedures. His data-driven approach offers patients a personalized path that preserves quality of life without compromising outcomes. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 40801]

Urologic oncologist Dr. Peter Carroll presents the latest research on active surveillance as a preferred approach for managing low-risk prostate cancer and selected cases of intermediate-risk disease. Drawing from two decades of UCSF data, he explains how long-term outcomes support the safety and effectiveness of delaying treatment for carefully monitored patients. Carroll emphasizes that surveillance decisions should be guided by MRI imaging, PSA density, cancer volume, histologic subtype, and genomic testing. He notes that while many men experience gradual changes over time, only a small percentage require immediate treatment. Carroll also discusses innovations such as AI-assisted pathology and risk profiling to reduce unnecessary procedures. His data-driven approach offers patients a personalized path that preserves quality of life without compromising outcomes. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 40801]

Urologic oncologist Dr. Peter Carroll presents the latest research on active surveillance as a preferred approach for managing low-risk prostate cancer and selected cases of intermediate-risk disease. Drawing from two decades of UCSF data, he explains how long-term outcomes support the safety and effectiveness of delaying treatment for carefully monitored patients. Carroll emphasizes that surveillance decisions should be guided by MRI imaging, PSA density, cancer volume, histologic subtype, and genomic testing. He notes that while many men experience gradual changes over time, only a small percentage require immediate treatment. Carroll also discusses innovations such as AI-assisted pathology and risk profiling to reduce unnecessary procedures. His data-driven approach offers patients a personalized path that preserves quality of life without compromising outcomes. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 40801]

Urologic oncologist Dr. Peter Carroll presents the latest research on active surveillance as a preferred approach for managing low-risk prostate cancer and selected cases of intermediate-risk disease. Drawing from two decades of UCSF data, he explains how long-term outcomes support the safety and effectiveness of delaying treatment for carefully monitored patients. Carroll emphasizes that surveillance decisions should be guided by MRI imaging, PSA density, cancer volume, histologic subtype, and genomic testing. He notes that while many men experience gradual changes over time, only a small percentage require immediate treatment. Carroll also discusses innovations such as AI-assisted pathology and risk profiling to reduce unnecessary procedures. His data-driven approach offers patients a personalized path that preserves quality of life without compromising outcomes. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 40801]

Urologic oncologist Dr. Peter Carroll presents the latest research on active surveillance as a preferred approach for managing low-risk prostate cancer and selected cases of intermediate-risk disease. Drawing from two decades of UCSF data, he explains how long-term outcomes support the safety and effectiveness of delaying treatment for carefully monitored patients. Carroll emphasizes that surveillance decisions should be guided by MRI imaging, PSA density, cancer volume, histologic subtype, and genomic testing. He notes that while many men experience gradual changes over time, only a small percentage require immediate treatment. Carroll also discusses innovations such as AI-assisted pathology and risk profiling to reduce unnecessary procedures. His data-driven approach offers patients a personalized path that preserves quality of life without compromising outcomes. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 40801]

ReferencesFront. Immunol 2020. 03 February Sec. T Cell BiologyGeneReviews®[ [updated 2024 Feb 1] Seattle (WA): University of Washington, Seattle;Open Biol. 2020 Dec 16;10(12):200295.Cell. 1989 May 19;57(4):645-58. Journal of Genetics and Genomics 2020.V. 47, Issue 1, 20 January Pages 17-26Plant/Paige. 1975 "In the Light". on Physical Graffitihttps://music.youtube.com/watch?v=pNo1nS_JV5k&si=aD1HwJTkegLhjRCRLodge, J. 1969. "Candle of LIfe" To Our Children's Children." lp. Moody Blueshttps://music.youtube.com/watch?v=BVkIUY2s-7o&si=F5GrPlT-hklKTTGqDobson .B. 1961. "Morning Dew" Grateful Dead Europe 72'. lphttps://music.youtube.com/watch?v=jYR3sBmomgQ&si=vLBLIStvXYBFoaJc

In this episode of Behind the Genes, we explore how Artificial Intelligence (AI) is being applied in genomics through cross-sector collaborations. Genomics England and InstaDeep are working together on AI and machine learning-related projects to accelerate cancer research and drive more personalised healthcare. Alongside these scientific advances, our guests also discuss the ethical, societal and policy challenges associated with the use of AI in genomics, including data privacy and genomic discrimination. Our guests ask what responsible deployment of AI in healthcare should look like and how the UK can lead by example. Our host, Francisco Azuaje, Director of Bioinformatics Genomics England is joined by Dr Rich Scott, Chief Executive Officer at Genomics England Karim Beguir - Chief Executive Officer at InstaDeep Harry Farmer – Senior Researcher at Ada Lovelace Institute If you enjoyed today's conversation, please like and share wherever you listen to your podcasts. And for more on AI in genomics, tune in to our earlier episode: Can Artificial Intelligence Accelerate the Impact of Genomics? "In terms of what AI's actually doing and what it's bringing, it's really just making possible things that we've been trying to do in genomics for some time, making these things easier and cheaper and in some cases viable. So really it's best to see it as an accelerant for genomic science; it doesn't present any brand-new ethical problems, instead what it's doing is taking some fairly old ethical challenges and making these things far more urgent."   You can download the transcript, or read it below.   Francisco: Welcome to Behind the Genes. [Music plays] Rich: The key is to deliver what we see at the heart of our mission which is bringing the potential of genomic healthcare to everyone.  We can only do that by working in partnership.  We bring our expertise and those unique capabilities.  It's about finding it in different ways, in different collaborations, that multiplier effect, and it's really exciting.  And I think the phase we're in at the moment in terms of the use of AI in genomics is we're still really early in that learning curve. [Music plays] Francisco: My name is Francisco Azuaje, and I am Director of Bioinformatics at Genomics England.  On today's episode I am joined by Karim Beguir, CEO of InstaDeep, a pioneering AI company, Harry Farmer, Senior Researcher at the Ada Lovelace Institute, and Rich Scott, CEO of Genomics England.  Today we will explore how Genomics England is collaborating with InstaDeep to harness the power of AI in genomic research.  We will also dive into the critical role of ethical considerations in the development and application of AI technologies for healthcare.  If you've enjoyed today's episode, please like, share on wherever you listen to your podcasts. [Music plays] Let's meet our guests. Karim: Hi Francisco, it's a pleasure to be here.  I am the Co-Founder and CEO of InstaDeep and the AI arm of BioNTech Group, and I'm also an AI Researcher. Harry: I'm Harry Farmer, I'm a Senior Researcher at the Ada Lovelace Institute, which is a think-tank that works on the ethical and the societal implications of AI, data and other emerging digital technologies, and it's a pleasure to be here. Rich: Hi, it's great to be here with such a great panel.  I'm Rich Scott, I'm the CEO of Genomics England. Francisco: Thank you all for joining us.  I am excited to explore this intersection of AI and genomics with all of you.  To our listeners, if you wish to hear more about AI in genomics, listen to our previous podcast episode, ‘Can Artificial Intelligence Accelerate the Impact of Genomics', which is linked in this podcast description. Let's set the stage with what is happening right now, Rich, there have been lots of exciting advances in AI and biomedical research but in genomics it's far more than just hype, can you walk us through some examples of how AI is actually impacting genomic healthcare research? Rich: Yeah, so, as you say, Francisco, it is a lot more than hype and it's really exciting.  I'd also say that we're just at the beginning of a real wave of change that's coming.  So while AI is already happening today and driving our thinking, really we're at the beginning of a process.  So when you think about how genomics could impact healthcare and people's health in general, what we're thinking about is genomics potentially playing a routine part in up to half of all healthcare encounters, we think, based on the sorts of differences it could make in different parts of our lives and our health journey.  There are so many different areas where AI, we expect, will help us on that journey.  So thinking about, for example, how we speed up the interpretation of genetic information through to its use and the simple presentation of how to use that in life, in routine healthcare, through to discovery of new biomarkers or classification that might help us identify the best treatment for people.  Where it's making a difference already today is actually all of those different points.  So, for example, there's some really exciting work we're doing jointly with Karim and team looking at how we might use classification of the DNA sequence of tumours to help identify what type of tumour - a tumour that we don't know where it's come from, so what we call a ‘cancer of unknown primary' - to help in that classification process.  We're also working with various different people who are interested in classification for treatment and trials, but there's also lots in between recognising patterns of genomic data together with other complex data.  So we've been doing a lot of work bringing image data together with genomic data and other health data so that you can begin to recognise patterns that we couldn't even dream of.  Doing that hand in hand with thinking about what patients and participants want and expect, how their data is used and how their information is held, bringing it all together and understanding how this works, the evidence that we need before we can decide that a particular approach is one that policymakers, people in healthcare want to use, is all part of the conversation. Francisco: Thank you, Rich, for speaking of cutting-edge AI applications and InstaDeep.  Karim, could you give us a glimpse into your work and particularly how your technologies are tackling some of the biggest challenges in genomic research? Karim: Absolutely, and I think what's exciting is we've heard from Rich and, you know, this is like the genomics expertise angle of things and I come from the AI world and so do most of the InstaDeep team.  And really what's fascinating is this intersection that is being extremely productive at the moment where technologies that have been developed for like multiple AI applications turn out to be extremely useful in understanding genomic sequences.  This is a little bit, our journey, Francisco.  Back in 2021/2022 we started working on the very intriguing question at the time of could we actually understand better genomic sequences with the emerging technologies of NLP, natural language processing.  And you have to put this in context, this was before even the word ‘generative AI' was coined, this was before ChatGPT, but we had sort of like an intuition that there was a lot of value in deploying this technology.  And so my team, sort of like a team of passionate experts in research and engineering of AI, we tackled this problem and started working on it and the result of this work was our nucleotide transformer model which we have open sourced today; it's one of the most downloaded, most popular models in genomics.  And what's interesting is we observed that simply using the technologies of what we call ‘self-supervised learning' or ‘unsupervised learning' could actually help us unlock a lot of patterns. As we know, most of genomics information is poorly understood and this is a way actually, with using the AI tool, to get some sense of the structure that's there. So how do we do this?  We basically mask a few aspects of the sequence and we ask the system to figure them out.  And so this is exactly how you teach a system to learn English, you know, you are teaching it to understand the language of genomics, and, incredibly, this approach when done at scale - and we train a lot on the NVIDIA Cambridge-1 supercomputer – allows you to have results and performances that are matching multiple specialised models.  So until then genomics and use of machine learning for genomics was for a particular task, I would have developed a specific model using mostly supervised learning, which is, I am showing you a few examples, and then channelled these examples and tried to match that, and so essentially you had one model per task.  What's really revolutionary in this new paradigm of AI is that you have a single model trained at very largescale, the AI starts to understand the patterns, and this means that very concretely we can work with our partners to uncover fascinating relationships that were previously poorly understood.  And so there is a wealth of potential that we are exploring together and it's a very exciting time. Francisco: What you're describing really highlights both the potential and the opportunities but also the responsibility we have with these powerful tools, its power, and this brings up some important ethical considerations.  And we have Harry…  Harry, we have talked about ethics frameworks in research for decades but AI seems to be rewriting the rulebook.  For your work at the Ada Lovelace Institute what makes AI fundamentally different from previous technologies when it comes to ethical considerations and how does this reshape our approach to ensuring these powerful tools benefit society as a whole? Harry: So I think when you are considering these sorts of ethical questions and these sorts of ethical challenges posed by AI and genomics it really depends on the sort of deployment that you're looking at.  From the conversation we've had so far, I think what's been hinted at is some of the diversity of applications that you might be using AI for within the context of genomics and healthcare.  So I think there's obviously big advances that have been alluded to in things like drug discovery, in things like cancer and cancer diagnosis, also these advances around gene editing, all of which have been on steroids, by artificial intelligence and particularly machine learning and deep learning. The area that we have been looking at at the Ada Lovelace Institute, and this was a project that we were doing in collaboration with the NCOB, the Nuffield Council on Bioethics, was looking at what we were calling ‘AI-powered genomic health prediction', which is very related to a technique called ‘polygenic scoring', for those who might be interested.  And that's looking at the emerging ability to make predictions about people's future health on the basis of their DNA, and it was thinking about what that ability might mean for UK society and also for how we are thinking about and delivering healthcare in the UK. Now, thinking about what the ethical challenges might be for that, I think you need to think about what specifically AI is bringing to that technique, so what it's bringing to genomic health prediction.  I think with some of the other deployments, the list of things that AI is bringing is quite similar, so it's helping with data collection and processing, so speeding up and automating data collection and preparation processes that otherwise are quite slow and very labour-intensive.  AI's also helping with the analysis of genomic and phenotype data, so helping us to understand the associations between different genomic variations and between observable traits, and this is something which without AI can often be prohibitively complex to do, and it's also sometimes suggested that on the deployment end AI can be a tool that can help us use genomic insight in healthcare more widely.  So one example of this might be using an AI chat bot to explain to a patient the results of a genomic test.  That's something that's only been mooted and I don't think there are current examples of that at the moment but that's one of the downstream applications of AI in the context of genomics. So in terms of what AI's actually doing and what it's bringing, it's really just making possible things that we've been trying to do in genomics for some time, making these things easier and cheaper and in some cases viable.  So really it's best to see it as an accelerant for genomic science; it doesn't present any brand-new ethical problems, instead what it's doing is taking some fairly old ethical challenges and making these things far more urgent.  So in terms of what those problems actually are, some of the big ones will be around privacy and surveillance, genomic health predictions produce a lot of intimate sensitive data about people and generating those insights requires the collection and the storage and the processing of a lot of very sensitive data as well.  We also have issues related to privacy around genomic discrimination, so this is the worry that people will be treated differently and in some cases unfairly on the basis of health predictions made about them.  And one of the really typical examples here is the worry that people might face higher insurance costs if they're found through genomic testing to be more likely to develop particular diseases over their life course. And then you also have a bunch of issues and questions which are more structural, so these are questions about how the availability of this kind of insight into people's future health might change or put pressure on existing ways of thinking about health and thinking about healthcare and some extreme cases thinking about the social contract.  So these are questions like does the viability of genomic health prediction lead to a radically more preventative approach to healthcare and what might this mean for what the state demands of you as a user of healthcare and as a recipient of that.  And there are also some important questions about the practicalities of delivering genomic medicine in the NHS, so questions like how does the NHS retain control and sovereignty over genomic analysis and data capacities, how do we test their efficacy at a public health level, and also – and this is something that we might talk about a bit later – what's the best deployment model for these capacities.  So that's some of the ethical and I think policy challenges that we need to be dealing with in this space. Francisco: Thank you, Harry.  And those principles you have outlined provide a solid foundation for discussing different types of applications. [Music plays] Let's talk about the InstaDeep and Genomics England partnership that is investigating the application of InstaDeep's powerful foundation model, the nucleotide transformer, and other cutting edge techniques to address several challenges in cancer research.  I have the privilege of working closely with this partnership and the potential here is immense.  Karim, could you break down for our listeners what you are working on together and what innovations you are aiming for? Karim: Absolutely, Francisco.  Actually, we are very excited by the collaboration with Genomics England.  Genomics England not only has one of the best data assets in the world when it comes to genomics, like a very well curated dataset but also a wealth of expertise on these topics, and on my side the InstaDeep team brings fundamental knowhow of machine learning models but also, as you mentioned, like powerful developed models already, such as our nucleotide transformer and others.  The culture of InstaDeep has always been to build AI that benefits everyone – this is literally in our mission – and so in particular, specifically on like current topics, really like the goal is to try to identify partners between genomic sequences of patients and the particular phenotypes or approaches.  And one of the key projects, which I mentioned that, is the one of cancer of unknown primary origin.  So when you have situations where you are not sure where a particular cancer emerged from it is critical to be able to extract this information to have the best potential care, and this is actually something where understanding of genomic sequences can bring this capability.  And so we've been getting some successful results in the collaboration but in many ways this is just the beginning.  What we are seeing is a great wealth of possibilities linking genotypes, so the information which is on the sequences themselves, the genomic sequences, and phenotypes, like the particular state of the patient, and the fact that the Genomics England team has those joint datasets creates incredible opportunities.  So we are looking at this really like identifying together what are the most useful ‘low-hanging fruits', if you want, in terms of like potentially improving a patient's care and moving forward from that. Francisco: And this collaborative approach you are describing raises questions about accelerating innovation in general.  When two organisations like Genomics England and InstaDeep come together it's like a multiplier effect in terms of expertise, data, and other resources.  Could you both share how this partnership is accelerating discoveries that might have taken years? Rich: Yeah, I mean, I think this…  Francisco, you frame it really nicely because this is what makes it so exciting to be in our position at Genomics England because what we do is we bring the particular understanding and expertise, digital infrastructure and custodianship of the National Genomic Research Library together, but actually the key is bringing the potential of genomic healthcare to everyone.  We can only do that by working in partnership, we bring our expertise and those capabilities.  And, as you say, it's about finding it in different ways, in different collaborations, that multiplier effect, and it's really exciting.  And I think the phase we're in at the moment in terms of the use of AI in genomics is we're still really early in that learning curve.  And so, as you've heard already through what Karim and I have said and also what Harry has said, there are multiple different aspects that we need to look at together, bringing different angles and understandings, and we see ourselves…  We often describe ourselves as a ‘data and evidence engine', that final word ‘evidence' is really important and it comes in the round.  So Harry really eloquently talked about a number of different considerations from an ethical perspective that need to be there.  What we need if we're going to move genomics forwards in terms of its potential to make a difference for people's lives, we need evidence around clinical efficacy of different approaches, that's absolutely a given and everyone always jumps at…  so it's almost first in line.  We need understanding about the health economics, you know, how much difference does it make for a particular investment, is it worth that investment.  Critically, it also is founded on, you know, how you might use this technology in different ways, how you use it in clinical pathways, you know, is it something that actually is addressing the particular questions which really hold back the delivery of better care.  Also in that evidence piece is an understanding of patients' and participants' expectations on how their data might be used, their expectations on privacy, the expectations that we have on understanding how equitable the use of a particular approach might be, or at least our understanding of how confident we are about the equity of the impact, and it's bringing together those different perspectives.  And that's one of the things that helps us construct the team at Genomics England so we have the expertise to help others access the data in the National Genomic Research Library for purposes our participants support but also help generate that sort of rounded package of evidence that will end up moving the dial.  So that it's not just about proving a cool widget, because that's great on its own, what drives Karim and the team is to make a difference in terms of outcomes, and that's exactly what drives us and our participants too. Francisco: And this and other partnership approaches brings up important questions about responsible innovation, and this naturally leads us to the next question for Harry, how do we harness these powerful tools when protecting our communities? Harry: Yeah, so if we are thinking about over-surveillance and the ways that vulnerable groups might be affected by the use of genomics and healthcare, I think we're talking about at least two different things here.  So one problems around the representativeness of data is it does lead to issues which you could classify as issues of differential accuracy.  So in the context of genomic prediction what you have is genomic predictive tools being more accurate for white Europeans and those with white European ancestry compared to other population groups.  And this is a product of the fact that genomic datasets and genomic predictions, the terminologies don't port well between different populations, which means if you train a genomic predictive tool on a bunch of people with white European ancestry the predictions you might make using that tool for other groups won't be as accurate as for the white Europeans.  And this can be actively harmful and dangerous for those in underrepresented groups because you are making predictions about people which just won't have the accuracy that you would expect in the context that you were deploying it. And I already mentioned this a bit in my previous answer, you have worries about discrimination, and there are a few different things here.  So with some historically marginalised groups and marginalised groups now there are longstanding historical sensitivities about being experimented on, about particular fears about eugenics and about being categorised in particular ways.  And it's worth saying here that there is obviously a racial dimension to this worry but I think there's also a class dimension, by which I mean you're far more vulnerable to being categorised unfavourably if you're poor or if you don't have a particular kind of status within society.  There is also within discrimination the idea that genomics might be used to explain away differences between different groups which in fact have a political or an economic basis.  So one example of this was during the COVID-19 pandemic, there were attempts by some commentators to explain away the fact that non-white communities had worse rates of mortality from COVID to try and attribute a genetic or a genomic basis to those differences rather than looking at some of the socioeconomic factors behind that.  So those are some worries as well. Now, when it comes to protecting particular groups I think there are a few things that can be done fairly straightforwardly.  So, one is work to improve the diversity and the representativeness of datasets.  Obviously, that's easier said than done, though it's a very clear thing that we can aspire towards and there is good work, I'm aware, that is going on in this space, some of which is being spearheaded by Genomics England, amongst other groups.  Another is just being very careful about how the results of population level genomic studies are communicated to avoid giving that impression of explaining away differences between different groups simply as things determined by genomics about which we can do nothing rather than things which have historical or socioeconomic bases.  But I also think the broader lesson is that some of these harms and these forms of discrimination are things that could theoretically affect anyone; they're not just limited to affecting marginalised groups. Genomic health predicting can produce bases for all of us to be discriminated against, things that have nothing to do with our race, our class, our sex or any other protected characteristic.  So I think there has to be thinking about how we establish or sure up more universal protections against genomic discrimination.  One thing that we can do here is simply stronger data protection law, and one of the things that we talk about in some of our reports is that how data protection law as it stands could do with being less ambiguous when it comes to how it treats genomic data and phenotype data produced as a result of genomic analysis. [Music plays] Francisco: Harry, you are in a unique position at the Ada Lovelace Institute where you bridge this gap between AI developers, researchers, policymakers and the public.  Your recent report on AI in genomics with the Nuffield Council on Bioethics offers an important blueprint for responsible AI innovation in general, so based on this cross-sector perspective, what guiding principles do we need to embrace as we navigate this intersection of AI and genomics? Harry: So I think in addition to the specific recommendations we set out in the final report of that work - which is called ‘Predicting the Future of Health' and which you can find on our website and also on the NCOB website – I think one of the biggest messages was the importance of finding a deployment model for genomic health prediction that respects that technology's strengths, what it can actually do, because there are limitations to this technology, and also which avoids circumstances in which the associated risks are difficult to deal with.  So another way of putting this is that we need a deployment model that, as well as making sure that we're ready to cope with the risks of genomic health prediction, the things like law, regulation and governance also proactively tries to design out some of those risks and finds ways of deploying this technology such that those risks don't present themselves in either as extreme a manner or don't present themselves in ways which makes them difficult to deal with. So one question that we posed in our research was whether some ways of integrating genomic health prediction may present more challenges regarding privacy, discrimination and then these other challenges that we'd identified around dependency and fragility and others. And having looked at some of the different broad approaches to using genomic health prediction within the NHS and within the UK's health system, we found that one presented by far fewest of the risks identified above, while still presenting some of the most certain benefits of genomic health prediction.  And this was using it really primarily as a targeted diagnostic tool - and this is a vision in which the NHS uses genomic health prediction quite sparingly in the first instance - and in situations to improve treatment and outcomes for those who are seriously ill or who have been identified as needing to take particular precautions regarding their health.  We think the more situational vision has a few advantages.  So one, is it allows patient and people using the health service to retain greater control over data.  We think that can also have a positive knock-on effect for worries about discrimination.  And here what you have is the absence of those pressures to share your data.  It means that it's easier for you as the user of the healthcare system to resist genomic discrimination simply by keeping your data private.  And there are some cases where that option… it shouldn't be the only option but where that option is really important. And then also one of the features of this vision is that the smaller scale of the use of genomic health prediction, presumed, can make outsourcing to third parties, which the NHS is probably likely to need to do in some cases.  It's also a vision, I think, that overall allows you to capture some of the more certain benefits to genomic health prediction which are about improvements to accuracy in predictions about people's future health at the margin, and therefore this is a deployment of this technology which is deploying it principally to people who will benefit and we know will benefit from marginal improvements in accuracy to predictions made about their future health rather than wanting to deploy those marginal improvements to the vast majority of the population where the benefit is less certain.  So this is a vision we hope sets out a way of getting some of the more certain benefits of this technology while minimising some of those broader more systemic risks. Francisco: Thank you, Harry.  Karim? Karim: Totally agree with Harry about the need for smart regulation in the field so that we make sure we have good uses of the technology but avoid the potential pitfalls.  I wanted to emphasise two points which I believe are important.  First, we are really in a fast-moving situation when we look at like AI progress.  We have seen incredible improvements over the last ten years and in particular what we call ‘artificial general intelligence', which is essentially systems that are matching human cognitive abilities, are now around the corner.  This might sound surprising but literally the last obstacles to reach AGI are being solved right now, and this means that in the next 12-24 months you will have systems that are incredibly capable.  So this emphasises the need for the type of measures and type of smart approach that Harry has described.  And I would say when you look at the intersection of AI and genomics this is a particularly important one and why it's the case, because so far in genomics our obstacle has not been data, it has been interpretation of a flood of data.  The progress that AI is making, like I just described now, means that very soon extraordinary capabilities will be available to improve patients' outcomes.  I want to inject a sense of how important is our conversation today, given what is happening, an exponential progress in AI, exponentially growing data in genomics and relatively exponential potential to build the technology for good.  But, like in other fields, we see that AI is an extremely powerful technology and we need to make sure it is used for good in fact and this is why the conversation that we have today is so important. Harry: Obviously I agree with the conclusion to all of this, is that we need to think very hard about the way that artificial intelligence and its deployment in healthcare and also just in many different walks of life is going to be affecting the way we think about public service delivery, affecting the way that we think about scientific development.  It's worth noting, though, that I think one of the biggest challenges from a policy perspective on artificial intelligence is being able to distinguish the wheat from the chaff.  There are obviously areas where AI has made huge and incredibly impressive progress over the past few years and where we reasonably expect that to continue over the next few years, but there are also areas where some of the stories being told about the capabilities of future systems probably won't be matched by the reality, but there is I think a really big and very live debate about exactly what we can reasonably expect from these technologies and therefore what the deployments of them are. Francisco: Thank you.  We are approaching the end of the episode and I'd like to conclude with a couple of questions.  Genomics England has built quite an ecosystem of industry partnerships, how do collaborations like the one with InstaDeep fit into your broader mission for the company? Rich: So linking this to the conversation that we've just been having, which is AI is making a real difference in terms of technologies that we can test, we can develop evidence on, and that is rightly creating excitement, I think our approach…  The expectation of our participants is that our role is to sit there and help people develop evidence and you can make judgments on policy based on those and that is what will drive adoption.  I think the thing that really excites me for the UK, most particularly in genomics, is our ability to be the place in the world where you can come with a new technology, whether it's genomic sequencing technology, whether it's a genomic AI approach to train that to develop evidence on its efficacy, and, if it's proven to be effective to be worth the bang for the buck to perform to the expectations that patients, the public, would have of it in terms of equity and so forth also to deploy it.  I think there is a real reason for excitement around that and it's a real opportunity that the government has highlighted and that we absolutely buy into that the UK can be the best place to do that for academics and for industry.  And our participants see real opportunity and are eager for that work to be done so that we have the evidence on which to decide what should be deployed and where.  We see opportunities in all sorts of different areas, so certainly in terms of drug discovery and all the way through to simplifying tasks which at the moment just limit the rate at which the existing uses of genomics in healthcare can happen. So I think there's opportunities across the whole length, if you like, the sort of end to end, and the breadth of opportunity, and industry, companies like InstaDeep and others that we work with, are really crucial to that.  And what we do is think about the digital infrastructure we need to, you know, have those teams able to interact with within the National Genomic Research Library carrying out their approved research projects.  Also what support they need, and that comes in different shapes and sizes, depending on the ask and also the company.  So sometimes sort of leaning in more, particularly at the start of programmes, to help people shape the question, working with our participants, thinking about the wider evidence that you might need, for example, those sort of things that Harry's touched on, but also thinking about what hands-on support companies need, because not every company is anywhere close to Karim and InstaDeep's expertise.  Sometimes this is also about supporting people to have some of those tools that they don't have or some of the knowhow that's very specific to areas of genomics, so it's absolutely crucial to it.  And I think that point of the UK being the place to come and develop that evidence in its full breadth so that policy decisions can be made not based on hype but on evidence in the round, on what will make a difference. Francisco: And, Karim, looking ahead, also in retrospect, what have been your key learnings about making this cross-sector partnership work? Karim: We live in an extraordinary time and I want to emphasise the potential of scientific discovery in the next two or three years.  AI is going to move from, let's say, digital style, you know, technologies like coding and maths towards more like science and biology.  In particular, genomics is going to be a fascinating area in terms of potential, and I agree with Rich and Harry, it's all in the end about proving on the ground the potential of those capabilities.  And at InstaDeep we are passionate about the tech – I think you might have felt that – but we're also passionate about the applications.  The best results come when you bring expertise from multiple domains; machine learning and AI experts will require the expertise of genomic experts, biologists, healthcare practitioners, to be able to translate the potential of those technologies in concrete outcomes.  And we've seen this on multiple successful projects we've done with Genomics England but really this suggests that we are going to have in the next 3-5 years way more progress than we had in the last five and really my wish is that collectively we seize this opportunity and we do it in a responsible and thoughtful manner. [Music plays] Francisco: We'll wrap up there.  Thank you to our guests, Karim Beguir, Harry Farmer and Rich Scott, for joining me today as we discuss the role of AI in genomics research.  If you wish to hear more like this, please subscribe to Behind the Genes on your favourite podcast app.  Thank you for listening.  I have been your host, Francisco Azuaje.  This podcast was edited by Bill Griffin at Ventoux Digital and produced by Naimah Callachand. [Music plays]    

The deficits from the lead poisoning continue to intensify, Shannon channels her anger and grief into holding the people who hurt her son responsible.LEAD how this story ends is up to us is a true story written and produced by Shannon Burkett. Co-produced by Jenny Maguire. Directed by Alan Taylor. Starring Merritt Wever, Alessandro Nivola, Cynthia Nixon, and Cooper Burkett.EP4 features Eboni Booth, Sasha Eden, Kevin Kane, April Matthis, Alysia Reiner, and Mandy Siegfried. Casting by Alaine Alldaffer and Lisa Donadio. Music by Peter Salett. Sound Design by Andy Kris. Recording Engineer Krissopher Chevannes.For corresponding visuals and more information on how to protect children from lead exposure please go to https://endleadpoisoning.org.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Welcome back to another episode of Brands and Barbed Wire.   This week we continue our Future of Beef series where we interview Nick Jorgensen with Jorgensen Land and Cattle.  We've interviewed the Jorgensen family before here on Brands and Barbed Wire which is an incredible episode if you haven't listened.  It's about the family's history in the Angus business and details the famous FBI raid on the ranch.   This episode from the Future of Beef focuses more on the technology they utilize on their ranch in SD.   We hope you enjoy the show and more information on the Future of Beef visit www.thefutureofbeef.com. Thanks to our sponsors Allied Genetic Resources www.alliedgeneticresources.com, The Grant Company at www.grantcompany.net, B.R. Cutrer Ranch www.brcutrer.com, Jorgensen Land and Cattle www.jorgensenfarms.com

In this episode of the AgCulture Podcast, Eric McNeilly, International Premier Account Manager at Alta Genetics, shares insights from his 49-year career in the global dairy industry. From managing herds of over 20,000 cows to restructuring troubled farms across six continents, Eric explains the systems, cultural dynamics, and technologies driving efficient dairy operations. Learn practical management strategies and how to future-proof your dairy business. Listen now on all major platforms!Meet the guest: Eric McNeilly has nearly five decades of experience in the dairy industry, including managing herds of over 200,000 cows and consulting across 22 countries. With deep expertise in labor efficiency, dairy systems, and genetics, he now serves as International Premier Account Manager at Alta Genetics.What you will learn: (00:00) Introduction(05:11) Managing large herds(14:11) Cross-cultural leadership(15:31) Farm restructuring systems(24:15) Genomics in breeding(28:23) Technology in dairy(37:01) Closing thoughtsDiscover the world of agriculture with the "Ag Culture Podcast".  This podcast will be a gateway for those passionate about agriculture to explore its global perspectives and innovative practices.Join Paul as he shares his experiences in the agricultural industry, his travels and encounters with important figures around the world.Available on YouTube, Spotify and Apple Podcasts.Subscribe at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠http://www.agculturepodcast.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ and keep an eye out for future episodes, bringing insights and stories from the vibrant world of agriculture.

HIV, superbugs, and standards—oh my! In this episode of Absolute Gene-ius, we explore the frontier of infectious disease research with Dr. Jesús Mingorance, researcher at Hospital Universitario La Paz in Madrid. His research is translational and uses digital PCR, qPCR, sequencing, and more.Dr. Mingorance walks us through his application of ultra-sensitive PCR methods to track HIV-2 viral loads—particularly in challenging cases where standard assays fall short. He shares how digital PCR enabled detection in samples where conventional tests failed, and how it's becoming essential for assay calibration and microbial quantification. He also dives into the endemic challenges of carbapenem-resistant Klebsiella pneumoniae in hospitals, revealing the clinical and epidemiological importance of quantifying pathogen load within the microbiome.In the career corner, Dr. Mingorance recounts his unconventional journey—from humanities student to biologist inspired by a single sentence about DNA. With humor and honesty, he reflects on the patience needed in science, the value of good questions, and the importance of mentoring new scientists. “Biology is beautiful,” he reminds us. We agree.Visit the Absolute Gene-ius pageto learn more about the guests, the hosts, and the Applied Biosystems QuantStudio Absolute Q Digital PCR System. 

- Overview of Bladder Cancer, Including Staging & Grading - Standard of Care - New Treatment Approaches - Update on Clinical Trials: How Clinical Trials Increase Your Treatment Options - The Role of Diagnostic Technologies, Genomics & Precision Medicine - Targeted Treatments: Predicting Response to Treatment - The Emerging Role of Immunotherapy - Communicating with Your Health Care Team About Quality-of-Life Concerns - Follow-Up Care Appointments & Plans - Guidelines to Prepare for Telehealth/Telemedicine Appointments, Including Technology, Prepared List of Questions & Discussion of OpenNotes - Nutrition & Hydration Concerns & Tips - Questions for Our Panel of Experts

Send us a textAI Pathology & Genomics: A New Benchmark for Predicting Gene MutationsIf you still think visual quantification is “good enough” in pathology, think again. In this 27th episode of DigiPath Digest, I break down four transformative abstracts that show how AI is shifting our diagnostic landscape—from breast cancer segmentation to fibrosis assessment, and all the way to spatial immunology and the evolving immunoscore.If you're still relying on manual scoring, static staging systems, or single-marker immunohistochemistry, this episode will challenge you to look deeper—literally and algorithmically.

- Overview of Bladder Cancer, Including Staging & Grading - Standard of Care - New Treatment Approaches - Update on Clinical Trials: How Clinical Trials Increase Your Treatment Options - The Role of Diagnostic Technologies, Genomics & Precision Medicine - Targeted Treatments: Predicting Response to Treatment - The Emerging Role of Immunotherapy - Communicating with Your Health Care Team About Quality-of-Life Concerns - Follow-Up Care Appointments & Plans - Guidelines to Prepare for Telehealth/Telemedicine Appointments, Including Technology, Prepared List of Questions & Discussion of OpenNotes - Nutrition & Hydration Concerns & Tips - Questions for Our Panel of Experts

The effects of the neurotoxin are taking their toll on Cooper as Shannon desperately tries to navigate the severity of their new reality.LEAD how this story ends is up to us is a true story written and produced by Shannon Burkett. Co-produced by Jenny Maguire. Directed by Alan Taylor. Starring Merritt Wever, Alessandro Nivola, Cynthia Nixon, and Cooper Burkett.E43 features Jenny Maguire, JD Mollison, Laith Nakli, Deirdre O'Connell, Carolyn Baeumler, Zach Shaffer, and Monique Woodley. Casting by Alaine Alldaffer and Lisa Donadio. Music by Peter Salett. Sound Design by Andy Kris. Recording Engineer Krissopher Chevannes.For corresponding visuals and more information on how to protect children from lead exposure please go to https://endleadpoisoning.org.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

If you want to know about sheep genetics in New Zealand, our guest this week, John McEwan, is the person to ask. John has been involved with genomics “since before genomics was a thing.”From discovering key reproductive genes and rolling out DNA parentage, to the sequencing of the sheep genome and the industry adoption of genomic selection, John takes us through the milestones that have shaped New Zealand sheep breeding. Tune in today to hear where we're heading next. Head Shepherd is brought to you by neXtgen Agri International Limited. We help livestock farmers get the most out of the genetics they farm with. Get in touch with us if you would like to hear more about how we can help you do what you do best: info@nextgenagri.com.Thanks to our sponsors at MSD Animal Health and Allflex, and Heiniger Australia and New Zealand. Please consider them when making product choices, as they are instrumental in enabling us to bring you this podcast each week.Check out Heiniger's product range HERECheck out the MSD range HERECheck out Allflex products HERE

Overall, the pharmaceutical industry is moving away from an approach where AI is task-driven, narrowly focused on a single, isolated problem. Instead, companies are embracing foundation models which, trained on very large and broad datasets, are versatile, and capable of tackling a range of complex challenges simultaneously. In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Brendan Frey, founder and chief innovation officer of Deep Genomics, an AI-first TechBio organisation working on a genome biology foundation AI platform. From Nobel Prizes connected to the company's work in the field, to mining RNA biology data and Deep Genomics' own foundation model for this – Frey explains why standard approaches are simply too slow and costly. You can also listen to episode 199a of the pharmaphorum podcast in the player below, download the episode to your computer, or find it - and subscribe to the rest of the series – on Apple Podcasts, Spotify, Overcast, Pocket Casts, Podbean, and pretty much wherever else you download your other podcasts from.

As the lead wreaks havoc on Cooper's development, Shannon searches for answers. Desperate to get a handle on what was happening to her son, she grabs onto a lifeboat - nursing school. Andy tries to piece together the past to make sense of the present.LEAD how this story ends is up to us is a true story written and produced by Shannon Burkett. Co-produced by Jenny Maguire. Directed by Alan Taylor. Starring Merritt Wever, Alessandro Nivola, Cynthia Nixon, and Cooper BurkettEP2 features Keith Nobbs and Frank Wood. Music by Peter Salett. Sound Design by Andy Kris. Recording Engineer Krissopher Chevannes. Casting by Alaine Alldaffer and Lisa Donadio.For corresponding visuals and more information on how to protect children from lead exposure please go to https://endleadpoisoning.org.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Watch my first-ever conversation with a political leader on the Alloutcoach show who has also transcended business, entrepreneurship, community service, women's rights advocacy and sports science. This episode uncovers a personal story and manifestation of character and integrity of an inspiring, dynamic, and powerful leader, Hon. Leela Aheer, former Canadian Minister of Culture, Multiculturalism, and Women's rights, musician, and activist throughout her journey of transformation into becoming a business executive, entrepreneur and expert in optimizing athletic performance.In addition to lessons on sportsmanship-centered leadership in business, you will discover the difference precision medicine with multi-omics and slightest variance in our microbiome DNA can have on creating gold medalists in sports, and champions in health, training, rehabilitation and recovery.

Did you know that breastfeeding may be the “biological norm,” but it is a learned skill for both mothers and babies. Join Food Sleuth Radio host and Registered Dietitian, Melinda Hemmelgarn for her conversation with Jennifer Smilowitz, Ph.D., Assistant Professor of Cooperative Extension in the Department of Nutrition, at the U. of CA, Davis, and Director of Scientific and Strategic Development for the International Milk Genomics Consortium. Smilowitz will discuss the multiple benefits of breastfeeding for maternal, child and planetary health, the policies needed to support breastfeeding, and how breast milk uniquely protects infants' health as well as contributes to sustainability and community resilience.  Note: August is World Breastfeeding MonthRelated Websites: https://www.milkgenomics.org/splash/

In this episode of Beyond the Thesis with Papa PhD, host David Mendes sits down with Dr. Karina do Santos Machado, a trailblazing young scientist from Brazil whose journey exemplifies the power of collaboration and open science in the global South. Karina shares her path from a childhood fascination with computers to becoming a principal investigator leading cutting-edge drug discovery research with global impact, all from her home base in Rio Grande.   Facing the challenges of limited funding, infrastructure hurdles, and fewer resources common to universities in developing countries, Karina highlights how resourcefulness and community spirit have been fundamental to her success. Collaboration is not only a choice but a necessity in the Brazilian scientific landscape. By building networks both within her institution and internationally, Karina has leveraged open science initiatives to propel her team onto the world stage, including successful participation in global drug discovery challenges such as Conscience's CACHE initiative for COVID-19 therapeutics.   As Karina explains, open science has been key in providing access to critical data, software, and partnerships, democratizing opportunities for smaller labs like hers. Her story is a testament to how determined scientists, even from under-resourced environments, can foster innovation and make tangible contributions to global health.   Karina dos Santos Machado holds a degree in Computer Engineering from the Universidade Federal de Rio Grande and a Master's and Ph.D. in Computer Science from the Pontifícia Universidade Católica of Rio Grande do Sul. Between 2018 and 2019, she worked as a postdoctoral fellowship in the NANO-D research group at INRIA in Grenoble, France. She is currently a Lecturer at FURG, working in the graduate programs in Health Sciences and Computer Science, where she coordinates the Computational Biology Laboratory. Her research focuses primarily on Bioinformatics and Data Science, including the following topics: Genomics, Machine Learning, Virtual Drug Screening, Molecular Docking, and Molecular Dynamics.   Three Inspiring Take-aways from my conversation with Karina: Collaboration is a Superpower: In environments where resources are scarce, building bridges—within your university and beyond—makes it possible to tackle complex scientific problems. Don't hesitate to ask for help, offer your expertise, and create interdisciplinary teams; together, you go further. Open Science Levels the Field: By embracing open-source tools, sharing data, and participating in global challenges, you can give your work international visibility and validation, regardless of your location or funding status. Open science isn't just a philosophy; it's a passport to global research networks and impact. Your Local Challenges Have Global Resonance: The unique scientific questions you face in your community, like drug resistance in tuberculosis, are shared by the worldwide research community. Your perspective and commitment to real-world problems can drive both local solutions and contribute to advancing science on a global scale.   Karina's journey proves that with innovation, community, and openness, you can thrive and lead in science, no matter where you start.  If you're curious about AI, biosciences, or just want to see how resilient, creative science happens outside the “usual” power centers, this episode is a must-listen. Reach out to Karina on LinkedIn, and check out the episode for more wisdom! Let's build a more open, global scientific community together.  See the resources section below for Daria Levina's links! This episode's resources: X | Karina Machado CONSCIENCE | Webpage CACHE Challenges | Webpage Thank you, Karina Machado! If you enjoyed this conversation with Karina, let her know by clicking the link below and leaving her a message on Linkedin: Send Karina Machado a thank you message on Linkedin! Click here to share your key take-away from this interview with David! Leave a review on Podchaser ! Support the show !   You might also like the following episodes: Daria Levina – Behind the Scenes of Graduate Admissions Morgan Foret – Demystifying Industry Careers Tina Persson –Leaving Academia and Embracing Industry Sylvie Lahaie – Navigating Stress and Anxiety in Graduate School

The first complete draft of the human genome was published back in 2003. Since then, researchers have worked both to improve the accuracy of human genetic data, and to expand its diversity, looking at the genetics of people from many different backgrounds. Three genetics experts join Host Ira Flatow to talk about a recent close examination of the genomes of 65 individuals from around the world, and how it may help researchers get a better understanding of genomic functioning and diversity.Guests:Dr. Christine Beck is an associate professor of genetics and genome sciences in the University of Connecticut Health Center and the Jackson Laboratory.Dr. Glennis Logsdon is an assistant professor of genetics and a core member of the Epigenetics Institute at the University of Pennsylvania.Dr. Adam Philippy is a Senior Investigator in the Center for Genomics and Data Science Research at the National Human Genome Research Institute at the NIH.Transcripts for each episode are available within 1-3 days at sciencefriday.com. Subscribe to this podcast. Plus, to stay updated on all things science, sign up for Science Friday's newsletters.

A mysterious dust fills a young family's apartment. The truth begins to unravel when the mother gets a call from the pediatrician - the monster deep within the walls has been unleashed. LEAD how this story ends is up to us is a true story written and produced by Shannon Burkett. Co-produced by Jenny Maguire. Directed by Alan Taylor. Starring Merritt Wever, Alessandro Nivola, Cynthia Nixon, and Cooper Burkett. EP1 features Zak Orth, Jenny Maguire, Daphne Gaines, and Micheal Gaston. Music by Peter Salett. Sound Design by Andy Kris. Recording Engineer Krissopher Chevannes. Casting by Alaine Alldaffer and Lisa Donadio.For corresponding visuals and more information on how to protect children from lead exposure please go to https://endleadpoisoning.org.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In this episode of The Dairy Podcast Show, Dr. Hinayah Rojas, from Purdue University, shares valuable insights into the rapidly evolving field of genomics in dairy cattle. Dr. Rojas breaks down the challenges and opportunities presented by longitudinal traits like milk production, discussing how genomic tools are helping to boost sustainability across the industry. Additionally, Dr. Rojas offers advice on balancing motherhood with a demanding professional life. Listen now on all major platforms!"The lactation curve is complex, but genomics allows us to select animals not only for higher milk production but also for better lactation persistence."Meet the guest: Dr. Hinayah Rojas de Oliveira is an Assistant Professor of Genomics and Animal Breeding at Purdue University. She holds a PhD in Animal Sciences, focusing on Genetics and Animal Breeding, from the Federal University of Viçosa in Brazil. Dr. Rojas has completed postdoctoral work at the University of Guelph and Purdue University and previously worked as a Geneticist at Lactanet Canada. Her research aims to develop statistical models that maximize genetic progress while preserving diversity in livestock species.Liked this one? Don't stop now — Here's what we think you'll love!What you'll learn:(00:00) Highlight(01:30) Introduction(02:35) Dr. Rojas's journey(08:52) Genomics in dairy cattle(11:55) Longitudinal traits(14:30) Genomic & efficiency(17:11) Sustainability & genomics(28:35) Final questionsThe Dairy Podcast Show is trusted and supported by innovative companies like:* Adisseo* Lallemand* Priority IAC* Evonik- ICC- AHV- Protekta- Natural Biologics- SmaXtec- Berg + Schmidt- dsm-firmenich

Scientists are beginning to understand that ageing is not a simply linear process. Instead, recent research appears to show that we age in three accelerated bursts; at about 40, 60 and 80 years old. To find out what might be going on, Ian Sample hears from Prof Michael Snyder, the director of the Center for Genomics and Personalised Medicine at Stanford University School of Medicine, who explains what the drivers of these bursts of ageing could be, and how they might be counteracted You can support the Guardian at theguardian.com/fullstorysupport

Lexi Silver is 15 years old. She lost both of her parents before she turned 11. That should tell you enough—but it doesn't. Because Lexi isn't here for your pity. She's not a sob story. She's not a trauma statistic. She's a writer, an advocate, and one of the most emotionally intelligent people you'll ever hear speak into a microphone.In this episode, Lexi breaks down what grief actually feels like when you're a kid and the adults around you just don't get it. She talks about losing her mom on Christmas morning, her dad nine months later, how the system let her down, and how Instagram trolls tell her she's faking it for attention. She also explains why she writes, what Experience Camps gave her, how she channels anger into poems, and what to say—and not say—to someone grieving.Her life isn't a Netflix drama. But it should be.And by the way, she's not “so strong.” She's just human. You'll never forget this conversation.RELATED LINKS• Lexi on Instagram: @meet.my.grief• Buy her book: The Girl Behind Grief's Shadow• Experience CampsFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

The science behind your garden hydrangeas involves far more than just planting and watering. Dr. Lisa Alexander, a research geneticist with the USDA Agricultural Research Service, takes us on a fascinating journey from her first days pollinating chestnut trees in a 70-foot bucket truck to her current work revolutionizing hydrangea breeding at the National Arboretum.Working from the heart of Tennessee's nursery country, Dr. Alexander explains how she's mapping the genetic diversity of oakleaf hydrangea across its six-state native range. Her team has identified six distinct genetic populations, some containing rare genes that might help plants survive drought or cold temperatures. This groundbreaking research comes at a critical time – they've discovered that urbanization has already caused these beautiful native plants to disappear from many previously recorded locations.The economic stakes are significant. Hydrangeas represent a $155 million industry, ranking as the second best-selling woody shrub behind roses. By understanding the genetic blueprint controlling traits like plant size, flower structure, and environmental adaptations, breeders can develop improved varieties that combine beauty with resilience.Dr. Alexander also discusses the exciting launch of "Hort Genomes" – a new initiative creating a dedicated home for specialty crop genomic data within the Journal of the American Society for Horticultural Science. This resource will accelerate research across horticultural fields by centralizing crucial genetic information previously scattered across publications or unavailable to the scientific community.Whether you're a backyard gardener admiring your hydrangeas or a scientist breeding the next generation of ornamental plants, this episode reveals the remarkable intersection of traditional horticulture with cutting-edge genomics that's shaping the future of our gardens.Read the JASHS article “Precipitation, Temperature, and Population Structure Influence Genetic Diversity of Oakleaf Hydrangea Throughout Its Native Range” at https://www.doi.org/10.21273/JASHS05255-22.Learn more about the American Society for Horticultural Science (ASHS) at https://ashs.org/.HortTechnology, HortScience and the Journal of the American Society for Horticultural Science are all open-access and peer-reviewed journals, published by the American Society of Horticultural Science (ASHS). Find them at journals.ashs.org.Consider becoming an ASHS member at https://ashs.org/page/Becomeamember!You can also find the official webpage for Plants, People, Science at ashs.org/plantspeoplesciencepodcast, and we encourage you to send us feedback or suggestions at https://ashs.org/webinarpodcastsuggestion. Podcast transcripts are available at https://plantspeoplescience.buzzsprout.com.On LinkedIn find Sam Humphrey at linkedin.com/in/samson-humphrey. Curt Rom is at https://www.linkedin.com/in/curt-rom-611085134/. Lena Wilson is at https://www.linkedin.com/in/lena-wilson-2531a5141/. Thank you for listening! ...

Scientists are beginning to understand that ageing is not a simply linear process. Instead, recent research appears to show that we age in three accelerated bursts; at about 40, 60 and 80 years old. To find out what might be going on, Ian Sample hears from Prof Michael Snyder, the director of the Center for Genomics and Personalised Medicine at Stanford University School of Medicine, who explains what the drivers of these bursts of ageing could be, and how they might be counteracted. Help support our independent journalism at theguardian.com/sciencepod

Michelle Andrews built a career inside the pharma machine long before anyone knew what “DTC” meant. She helped launch Rituxan and watched Allegra commercials teach America how to ask for pills by name. Then she landed in the cancer fun house herself, stage 4 breast cancer, and learned exactly how hollow all the “journey” slide decks feel when you're the one circling the drain.We talk about what happens when the insider becomes the customer, why pill organizers and wheat field brochures still piss her off, and how she fired doctors who couldn't handle her will to live. You'll hear about the dawn of pharma advertising, the pre-Google advocacy hustle, and what she wants every brand team to finally admit about patient experience.If you've ever wondered who decided windsurfing was the best way to sell allergy meds—or what happens when you stop caring if you make people uncomfortable—listen up.RELATED LINKSMichelle Andrews on LinkedInTrinity Life Sciences – Strategic AdvisoryJade Magazine – Ticking Time Bombs ArticleNIHCM Foundation – Breast Cancer StoryFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Intelligence Notes: 4IR Genomics: AI Engineered Genetic Injections (Biomedical-Vaccine Warfare). Days of Noah Tech/ Fallen Watcher Technologies/ Augmentation via Transhumanism/ Biblical Eschatology (Genesis 6/ Matthew 24 ) Nephilim Tech, Giants , Hybrids, Genetic Monsters. Welcome to the: (Great Biological Reset).

Dr. Anne Marie Morse walks into the studio like a one-woman Jersey Broadway show and leaves behind the best damn TED Talk you've never heard. She's a neurologist, sleep medicine doc, narcolepsy expert, founder of D.A.M.M. Good Sleep, and full-time myth buster in a white coat. We talk about why sleep isn't a luxury, why your mattress does matter, and how melatonin is the new Flintstones vitamin with a marketing budget. We unpack the BS around sleep hygiene, blow up the medical gaslighting around “disorders,” and dig into how a former aspiring butterfly became one of the loudest voices for patient-centered science. Also: naps, kids, burnout, CPAPs, co-sleeping, airport pods, the DeLorean, and Carl Sagan. If you think you're getting by on five hours of sleep and vibes, you're not. This episode will make you want to take a nap—and then call your doctor.RELATED LINKSdammgoodsleep.com: https://www.dammgoodsleep.comLinkedIn: https://www.linkedin.com/in/anne-marie-morse-753b2821/Instagram: https://www.instagram.com/dammgoodsleepDocWire News Author Page: https://www.docwirenews.com/author/anne-marie-morseSleep Review Interview: https://sleepreviewmag.com/practice-management/marketing/word-of-mouth/sleep-advocacy-anne-marie-morse/Geisinger Bio: https://providers.geisinger.org/provider/anne-marie-morse/756868SWHR Profile: https://swhr.org/team/anne-marie-morse-do-faasm/FEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Check out the TIES Sales Showdown at www.tx.ag/TIESVisit The Sales Lab at https://thesaleslab.org and check out all our guests' recommended readings at https://thesaleslab.org/reading-listTo listen to The Sales Lab Podcast on your favorite apps, visit https://thesaleslab.simplecast.com/ and select your preferred method of listening.Connect with us on Facebook at https://www.facebook.com/saleslabpodcastConnect with us on Linkedin at https://www.linkedin.com/company/thesaleslabSubscribe to The Sales Lab channel on YouTube at  https://www.youtube.com/channel/UCp703YWbD3-KO73NXUTBI-Q 

Scientific Sense ® by Gill Eapen: Prof. Trey Ideker is Professor of Medicine, Bioengineering and Computer Science, and former Chief of Genetics, at the University of California San Diego (UCSD). He is also the Director of the Bridge2AI Functional Genomics Data Generation Program and Co-Director of the Cancer Cell Map Initiative. Please subscribe to this channel:https://www.youtube.com/c/ScientificSense?sub_confirmation=1

Gigi Robinson grew up with Ehlers-Danlos syndrome, a disease that turns your joints into overcooked spaghetti. Instead of letting it sideline her, she built a career out of telling the truth about invisible illness. We talk about what it takes to grow up faster than you should, why chronic illness is the worst unpaid internship, and how she turned her story into a business. You'll hear about her days schlepping to physical therapy before sunrise, documenting the sterile absurdity of waiting rooms, and finding purpose in the mess. Gigi's not interested in pity or polished narratives. She wants you to see what resilience really looks like, even when it's ugly. If you think you know what an influencer does, think again. This conversation will challenge your assumptions about work, health, and what it means to be seen.RELATED LINKSGigi Robinson Website: https://www.gigirobinson.comLinkedIn: https://www.linkedin.com/in/gigirobinsonInstagram: https://www.instagram.com/itsgigirobinsonTikTok: @itsgigirobinsonA Kids Book About Chronic Illness: https://akidsco.com/products/a-kids-book-about-chronic-illnessFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

This episode features Dr. James Lu, CEO and Co-founder of Helix, discussing how precision medicine is evolving from specialty use to becoming a foundational element of mainstream healthcare. He explores the infrastructure, partnerships, and mindset shifts needed for health systems to scale genomic data and realize its full value.This episode is sponsored by Helix.

In this special episode of The Dairy Podcast Show, celebrating Cow Appreciation Day, Dr. Michael Schutz, Head of the Department of Animal Science at the University of Minnesota, shares updates on dairy cattle genetics and herd management. He covers everything from breakthroughs in genomics to colostrum management and industry-wide shifts in dairy science education and practice. Tune in now on your favorite podcast platform!"Computing capacity has revolutionized genetic evaluations, allowing us to manage data on a scale unimaginable decades ago."Meet the guest: Dr. Michael Schutz is the Department Head of Animal Science at the University of Minnesota. With a BS and MS in Animal Science from the University of Minnesota and a Ph.D. in Dairy Cattle Genetics from Iowa State University, he brings decades of experience in dairy cattle research and extension programs. A pioneer in dairy genetics, Dr. Schutz continues to lead efforts in education and innovation.Liked this one? Don't stop now — Here's what we think you'll love!What you'll learn:(00:00) Highlight(01:26) Introduction(04:00) Dairy extension(13:22) Herd management(17:07) Evolution in education(19:43) Colostrum quality(26:16) Computing capacity & genetics(32:54) Final three questionsThe Dairy Podcast Show is trusted and supported by innovative companies like:* Adisseo* Lallemand* Priority IAC* Evonik- SmaXtec- Berg + Schmidt- dsm-firmenich- Scoular- ICC- AHV- Protekta- Natural Biologics

Dr. Hao Nguyen presents focal therapy as a promising treatment option for carefully selected prostate cancer patients, especially those with intermediate-risk, localized disease. Unlike whole-gland treatments, focal therapy targets only the tumor while preserving healthy tissue, reducing the risk of side effects like urinary or sexual dysfunction. UCSF offers multiple approaches—high-intensity focused ultrasound, cryotherapy, and irreversible electroporation—selected based on tumor location and anatomy. Dr. Nguyen emphasizes the importance of precise imaging, MRI fusion biopsy, and genomic testing for patient selection and treatment planning. Early outcomes show encouraging results, with most patients avoiding surgery or radiation within two years and maintaining quality of life. While not yet standard first-line care, focal therapy is gaining traction through research and expert consensus. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 40804]

Episode Description:If you've ever wondered what happens when a Bronx-born pediatric nurse with stage 4 colon cancer survives, raises a kid, becomes a policy shark, and fights like hell for the ignored, meet Vanessa Ghigliotty. She's not inspirational. She's a bulldozer. We go way back—like pre-Stupid Cancer back—when there was no “young adult cancer movement,” just a handful of pissed-off survivors building something out of nothing. This episode is personal. Vanessa and I built the plane while flying it. She fought to be heard, showed up in chemo dragging her kid to IEP meetings, and never stopped screaming for the rest of us to get what we needed. We talk war stories, progress, side-eyeing advocacy fads, TikTok activism, gatekeeping, policy wins, and why being loud is still necessary. And yeah—she's a damn good mom. Probably a better one than you. You'll laugh. You'll cry. You'll want to scream into a pillow. Come for the nostalgia. Stay for the righteous anger and iced coffee.RELATED LINKSVanessa on LinkedInColorectal Cancer Alliance: Vanessa's StoryZenOnco Interview with VanessaFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Risa Arin doesn't just talk about health literacy. She built the damn platform. As founder and CEO of XpertPatient.com (yes, expert with no E), Risa's taking a wrecking ball to how cancer education is delivered. A Cornell alum, cancer caregiver, and ex-agency insider who once sold Doritos to teens, she now applies that same marketing muscle to helping patients actually understand the garbage fire that is our healthcare system. We talk about why she left the “complacent social safety” of agency life, how her mom unknowingly used her own site during treatment, what it's like to pitch cancer education after someone pitches warm cookies, and why healthcare should come with a map, a translator, and a refund policy. Risa brings data, chutzpah, and Murphy Brown energy to the conversation—and you'll leave smarter, angrier, and maybe even a little more hopeful.RELATED LINKS• XpertPatient.com• Risa Arin on LinkedIn• XpertPatient & Antidote Partnership• XpertPatient Featured on KTLA• 2024 Health Award BioFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Dr. Jamie Wells is back—and this time, she brought a book. We cover everything from biomedical design screwups to the glorified billing software known as the EHR. Jamie's new book, A Clinical Lens on Pediatric Engineering, is a masterclass in what happens when you stop treating kids like small, drunk adults and start designing medicine around actual human factors. We talk about AI in pediatric radiology, why drug repurposing might save lives faster than biotech IPOs, and the absurdity of thinking one-size-fits-all in healthcare still works.Jamie's a former physician, a health policy disruptor, a bioethicist, an MIT director, and a recovering adjunct professor. She's also a unicorn. We dig into the wonk, throw shade at bad design, and channel our inner Lisa Simpsons. This one's for anyone who ever wondered why kids' hospitals feel like hell and why “make it taste like bubblegum” might be the most important clinical innovation of all time. You'll laugh, you'll learn, and you might get angry enough to fix something.RELATED LINKSJamie Wells on LinkedInBook: A Clinical Lens on Pediatric Engineering (Amazon)Book on SpringerDrexel BioMed ProfileGlobal Blockchain Business CouncilJamie's HuffPost ArticlesFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In celebration of Pride Month, we're sharing two stories about coming out with the help of science. Part 1: After years of struggling with their gender identity, Parker Sublette finds inspiration in marine life. Part 2: Bullied as a kid for the sound of his voice, Garret Glinka begins to reclaim his confidence thanks to biology class. Parker Sublette is a comedian and speculative fiction writer living in Brooklyn, New York. She can usually be found scrambling around the city looking for any stage that will have her, or at home with her roommates and their two cats. Parker also sometimes hosts an open-mic in Bushwick, you can find her @parks_jokez on instagram. Garret Glinka: I wear two hats: one as a businessman with half a Master's in Business, and the other as a scientist, with another half in Biotechnology and Genomics, complemented by a Bachelor's in Biological Sciences. My background allows me to bridge the administrative and scientific worlds. Over the past six years, I've honed my expertise as a laboratory professional in both corporate and academic settings, helping operate and set up five laboratories domestically/internationally. I've been a technician, team leader, supervisor, and lab manager. As a member of the queer community, I bring kindness, authenticity, vulnerability, and positive influence to my leadership style. Now at Columbia University's Neuroscience Institute, I manage two labs, lead the Gender and Inclusion Mentoring Program, and coordinate the Lab Liaison Group, ensuring communication across the institute's departments and other lab managers. When I'm not dissecting Drosophila in New York City, or out to eat with Jersey City friends, I retreat to my family's farm in central New Jersey. There you'll find me tending to our goats and chickens, inspecting the crops, or racing dirt bikes with my three-year-old nephew, Jay. My life is a dynamic blend of science, leadership, community, and family, each enriching the other in unexpected ways. Learn more about your ad choices. Visit megaphone.fm/adchoicesSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In celebration of Pride Month, we're sharing two stories about coming out with the help of science. Part 1: After years of struggling with their gender identity, Parker Sublette finds inspiration in marine life. Part 2: Bullied as a kid for the sound of his voice, Garret Glinka begins to reclaim his confidence thanks to biology class. Parker Sublette is a comedian and speculative fiction writer living in Brooklyn, New York. She can usually be found scrambling around the city looking for any stage that will have her, or at home with her roommates and their two cats. Parker also sometimes hosts an open-mic in Bushwick, you can find her @parks_jokez on instagram. Garret Glinka: I wear two hats: one as a businessman with half a Master's in Business, and the other as a scientist, with another half in Biotechnology and Genomics, complemented by a Bachelor's in Biological Sciences. My background allows me to bridge the administrative and scientific worlds. Over the past six years, I've honed my expertise as a laboratory professional in both corporate and academic settings, helping operate and set up five laboratories domestically/internationally. I've been a technician, team leader, supervisor, and lab manager. As a member of the queer community, I bring kindness, authenticity, vulnerability, and positive influence to my leadership style. Now at Columbia University's Neuroscience Institute, I manage two labs, lead the Gender and Inclusion Mentoring Program, and coordinate the Lab Liaison Group, ensuring communication across the institute's departments and other lab managers. When I'm not dissecting Drosophila in New York City, or out to eat with Jersey City friends, I retreat to my family's farm in central New Jersey. There you'll find me tending to our goats and chickens, inspecting the crops, or racing dirt bikes with my three-year-old nephew, Jay. My life is a dynamic blend of science, leadership, community, and family, each enriching the other in unexpected ways. Learn more about your ad choices. Visit megaphone.fm/adchoices